WO2020256162A2 - 인슐린 유사 성장인자 수용체의 억제제를 이용한 인간 전분화능 줄기세포로부터의 글루타메이트성 신경세포 분화방법 및 이를 통해 마련된 글루타메이트성 신경세포 - Google Patents
인슐린 유사 성장인자 수용체의 억제제를 이용한 인간 전분화능 줄기세포로부터의 글루타메이트성 신경세포 분화방법 및 이를 통해 마련된 글루타메이트성 신경세포 Download PDFInfo
- Publication number
- WO2020256162A2 WO2020256162A2 PCT/KR2019/007266 KR2019007266W WO2020256162A2 WO 2020256162 A2 WO2020256162 A2 WO 2020256162A2 KR 2019007266 W KR2019007266 W KR 2019007266W WO 2020256162 A2 WO2020256162 A2 WO 2020256162A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- differentiation
- inhibitor
- insulin
- cells
- medium
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Definitions
- the present invention relates to a technique for rapidly preparing glutamate neurons from human pluripotent stem cells using an insulin-like growth factor receptor inhibitor.
- hPSCs Human Pluripotent Stem Cells correspond to stem cells with differentiation ability that can differentiate into almost all tissues of a living body among stem cells with the characteristics of self-proliferation and differentiation.
- these human pluripotent stem cells can be stably cultivated in large quantities, they can be applied to various fields including regenerative medicine, disease mechanism research, etc., especially as a substitute for human-derived tissues that are difficult to obtain and using the same Have.
- prior literature on the prior art prepared in connection with the technical improvement of the method of differentiation of human neurons using human pluripotent stem cells includes the "Method of Differentiation of Neural Stem Cells Using agarose Gel" in Korean Patent Publication No. 10-1182758. (Hereinafter referred to as'conventional technology') there is.
- the present invention was created to solve the above problems, and an object of the present invention is to provide a differentiation method capable of rapidly preparing glutamate neurons from human pluripotent stem cells.
- the method for differentiating glutamate neurons from human pluripotent stem cells using inhibitors of insulin-like growth factor receptors includes human pluripotent stem cells (hPSCs) containing N2 and B27.
- hPSCs human pluripotent stem cells
- the step A is in DMEM/F12 medium containing N2 and B27, an inhibitor of the BMP signaling system from 150 nM to 250 nM, an inhibitor of the TGF ⁇ signaling system from 5 ⁇ M to 15 ⁇ M, and an inhibitor of insulin-like growth factor receptor (IGF1R) from 500 nM to 1000 nM. It may be a step of inducing differentiation into neuroectoderm cells by culturing human pluripotent stem cells for 6 days in the additionally treated neuroectodermal differentiation induction medium.
- IGF1R insulin-like growth factor receptor
- the medium for inducing neuroectodermal differentiation may contain N2 in a volume of 0.4ml to 0.6ml and B27 in a volume of 0.5ml to 1.5ml based on 50ml of DMEM/F12 culture solution.
- the step B is a neuronal progenitor cell differentiation containing N2 in a volume of 0.4ml to 0.6ml and B27 in a volume of 0.5ml to 1.5ml based on the culture medium mixed with 25ml of DMEM/F12 culture and 25ml of Neurobasal culture. It may be a step of culturing the neuroectoderm cells induced differentiation through the step A in the induction medium for 7 days to induce differentiation into neuronal progenitor cells.
- step C after coating treatment with Poly-L-Ornithine and Laminin on the medium, C-1 inoculating the neural progenitor cells induced differentiation through the step B at a concentration of 5 ⁇ 10 4 Cells/cm 2 step; Neurobasal culture medium 50ml and B27 0.5ml to 1.5ml are included in the medium in which the coating treatment and inoculation of the neural progenitor cells are completed through the C-1 step, and BNDF 5ng/ml to 15ng/ml, GDNF 5ng/ml to 15ng/ml And a C-2 step of preparing a medium for inducing differentiation of glutamate neurons by further processing 180 ⁇ M to 220 ⁇ M of ascorbic acid.
- the glutamate neuron according to the present invention is prepared through the method of differentiating glutamate neurons from human pluripotent stem cells using the inhibitor of the insulin-like growth factor receptor described above.
- the induction of differentiation from human pluripotent stem cells into neuroectodermal cells can be achieved within a short period of time compared to the conventional one.
- the speed of cultivation and differentiation of the finally obtained glutamate neuron can be accelerated, so that a rapid differentiation operation can be performed compared to the prior art.
- the efficiency can be further maximized by using glutamate neurons derived from human pluripotent stem cells as an alternative model for the study of related disease mechanisms in human brain tissue.
- 1 is a flowchart of a method for differentiating glutamate neurons from human pluripotent stem cells using the inhibitor of the insulin-like growth factor receptor of the present invention.
- FIG. 2 is a graph comparing the expression patterns of specific genes of neuroectodermal cells according to whether or not an inhibitor of insulin-like growth factor receptor is applied.
- 3 is a graph comparing the expression patterns of specific genes of neuroectoderm cells according to dates when an inhibitor of insulin-like growth factor receptor is applied.
- Figure 4 is a photograph of observation and comparison of the subsequent differentiation process of neuroectodermal cells according to whether or not an inhibitor of insulin-like growth factor receptor is applied.
- 5 is an immunostaining experiment for confirming the characteristics of glutamate neurons obtained through the method of differentiating glutamate neurons from human pluripotent stem cells using the inhibitor of the insulin-like growth factor receptor of the present invention.
- FIG. 6 is a graph showing the results of confirming the expression ratio of TUBB3 in glutamate neurons obtained through the method of differentiating glutamate neurons from human pluripotent stem cells using the inhibitor of the insulin-like growth factor receptor of the present invention.
- Figure 8 is between glutamate neurons obtained through the differentiation method of glutamate neurons from human pluripotent stem cells using the inhibitor of the insulin-like growth factor receptor of the present invention and glutamate neurons obtained through a conventional differentiation method. This is a graph of the results of comparative analysis of gene expression patterns.
- hPSCs human pluripotent stem cells
- the neuroectoderm cell differentiation step (S100) is an inhibitor of the BMP signaling system (LDN193189), TGF ⁇ signaling in the neuroectoderm induction medium in which human pluripotent stem cells (hPSC) are cultured to induce differentiation into neuroectodermal cells. It is characterized by the additional treatment of systemic inhibitors (SB431542) and insulin-like growth factor receptor (IGF1R) inhibitors (GSK1838705A).
- BMP signaling system LDN193189
- TGF ⁇ signaling in the neuroectoderm induction medium in which human pluripotent stem cells (hPSC) are cultured to induce differentiation into neuroectodermal cells.
- SB431542 systemic inhibitors
- IGF1R insulin-like growth factor receptor
- the neuroectodermal cell differentiation step (S100) is an inhibitor of the BMP signaling system 150 nM to 250 nM in DMEM/F12 medium (Hyclone) containing N2 (Thermo Fisher) and B27 (Thermo Fisher).
- BMP signaling system 150 nM to 250 nM in DMEM/F12 medium (Hyclone) containing N2 (Thermo Fisher) and B27 (Thermo Fisher).
- Human pluripotent stem cells were cultured for 6 days in a medium for inducing neuroectodermal differentiation in which 5 ⁇ M to 15 ⁇ M of inhibitors of the TGF ⁇ signaling system and 500 nM to 1000 nM of inhibitors of insulin-like growth factor receptor (IGF1R) were additionally treated as neuroectodermal cells. Induce differentiation.
- IGF1R insulin-like growth factor receptor
- the medium for inducing neuroectodermal differentiation corresponding to the DMEM/F12 medium (manufactured by Hyclone) containing N2 and B27 contains N2 in a volume of 0.4 ml to 0.6 ml based on 50 ml of the DMEM/F12 culture solution, and contains B27. It is preferably included in a volume of 0.5ml to 1.5ml.
- the medium for inducing neuroectodermal differentiation contains N2 in a volume of 0.4 ml to 0.6 ml and B27 in a volume of 0.5 ml to 1.5 ml based on 50 ml of DMEM/F12 culture medium, and the BMP signaling system After additional treatment of 150 nM to 250 nM inhibitor of TGF ⁇ signaling system, 5 ⁇ M to 15 ⁇ M inhibitor of TGF ⁇ signaling system, and 500 nM to 1000 nM inhibitor of insulin-like growth factor receptor (IGF1R), human pluripotent stem cells (hPSC) were cultured within 6 days. Differentiation induction proceeds to neuroectodermal cells.
- IGF1R insulin-like growth factor receptor
- hPSC human pluripotent stem cells
- the medium for inducing neuroectodermal differentiation contains N2 in a volume of 0.5 ml and B27 in a volume of 1.0 ml based on 50 ml of DMEM/F12 culture, and 200 nM, an inhibitor of the BMP signaling system, TGF ⁇ It is prepared by additional treatment with 10 ⁇ M of an inhibitor of the signaling system and 500 nM of an insulin-like growth factor receptor (IGF1R) inhibitor.
- IGF1R insulin-like growth factor receptor
- culture for inducing neuroectodermal cell differentiation in DMEM/F12 medium may be performed in a respiratory environment of 5% CO 2 and a temperature environment of 37°C, but is not limited thereto.
- the inhibitor (GSK1838705A) of insulin-like growth factor receptor (IGF1R) added to DMEM/F12 medium (manufactured by Hyclone) prepared for differentiation of neuroectodermal cells is preferably in a concentration condition of 500 nM to 1000 nM.
- the insulin-like growth factor receptor (IGF1R) inhibitor (GSK1838705A) has a concentration of less than 500 nM, the level of expression of a specific gene that must be expressed by inducing differentiation into neuroectodermal cells is significantly lowered, and differentiation into neuroectodermal cells.
- IGF1R insulin-like growth factor receptor
- IGF1R insulin-like growth factor receptor
- GSK1838705A insulin-like growth factor receptor inhibitor
- the neuroectoderm cells differentiated through the neuroectoderm cell differentiation step (S100) are cultured in a medium for inducing neuronal progenitor cell differentiation to induce differentiation into a neural progenitor cell.
- the neural progenitor cell differentiation induction step (S200) is based on the culture solution mixed with 25 ml of DMEM/F12 culture solution (manufactured by Hyclone) and 25 ml of Neurobasal culture solution (manufactured by Thermo Fisher) from 0.4 ml to N2 (manufactured by Thermo Fisher).
- S100 neuroectoderm cell differentiation step
- the culture for inducing neuronal progenitor cell differentiation in a medium for inducing neuronal progenitor cell differentiation may be conducted in a respiratory environment of 5% CO 2 and a temperature environment of 37°C, but is not limited thereto.
- the medium for inducing neuronal progenitor cell differentiation is prepared in a state that contains N2 in a volume of 0.5 ml and B27 in a volume of 1.0 ml based on 25 ml of DMEM/F12 culture and 25 ml of Neurobasal culture.
- this step (S300) a process of inducing differentiation into liver glutamate neurons (Glutamatergic neuron) by culturing liver neuron progenitor cells differentiated through the differentiation inducing step (S200) in a glutamate neuron differentiation inducing medium. This is done.
- the neuron progenitor cells differentiated through the neuroprogenitor cell differentiation induction step (S200) are 5 ⁇
- the process of inoculating at a concentration of 10 4 Cells/cm 2 proceeds.
- Neurobasal culture solution product of Thermo Fisher
- 0.5 ml to 1.5 ml of B27 are included in the medium in which the coating treatment of Poly-L-Ornithine (product of Sigma) and Laminin (product of Sigma) in the medium and the inoculation of nerve progenitor cells are completed.
- BNDF Peprotech product
- GDNF Peprotech product
- ascorbic acid Peprotech product
- the medium for inducing differentiation of glutamate neurons contains 1.0 ml of B27 based on 50 ml of Neurobasal culture medium (manufactured by Thermo Fisher), 10 ng/ml of BNDF (manufactured by Peprotech), 10 ng/ml of GDNF (manufactured by Peprotech). And 200 ⁇ M of ascorbic acid (manufactured by Peprotech) are additionally treated.
- the culture for inducing glutamate neuron differentiation in the medium for inducing glutamate neuron differentiation may be carried out in a respiratory environment of 5% CO 2 and a temperature environment of 37°C, but is not limited thereto.
- the neural progenitor cells inoculated in the medium for inducing glutamate neuron differentiation are cultured for 7 days or longer to induce differentiation into glutamate neurons.
- glutamate neurons can be prepared at a faster rate than in the prior art, and the progress of various brain tissue and neuron-related studies conducted using this as an alternative model can achieve a higher level of efficiency. do.
- Figure 2 is a graph of the values organized and graphed based on test group 1 (LDN193189 + SB431542), which is an existing neuroectoderm differentiation induction method, and as a result, test groups 2 to 5 in which GSK1838705A was treated alone Although the induction of differentiation of neuroectodermal cells was not smooth, it was confirmed that test groups 6 to 9 mixed with LDN+SB produced good synergy.
- SOX1 was highly expressed, but SOX1 was not expressed in the early neuroectoderm, but was expressed at a later stage. It is an important gene that can be used.
- IGF1R insulin-like growth factor receptor
- BMP BMP signaling system
- TGF ⁇ TGF ⁇ signaling system
- IGF1R insulin-like growth factor receptor
- BMP BMP signaling system
- TGF ⁇ signaling system SB431542
- cells were obtained on the 3rd, 6th, and 9th days after the induction of differentiation, and mRNA levels were checked.
- test groups 11 and 12 treated with an inhibitor of insulin-like growth factor receptor (IGF1R) (GSK1838705A), especially in the case of the PAX6 gene, on day 3 test groups 11 and test groups.
- IGF1R insulin-like growth factor receptor
- the value of 12 shows the same gene expression as the test group 10 on the 9th day, and the level of expression has already been high from the 3rd day.
- NESTIN gene also showed higher gene expression than test group 10 on day 9 in test group 11 and test group 12 treated with inhibitor of insulin-like growth factor receptor (IGF1R) (GSK1838705A) as well.
- IGF1R insulin-like growth factor receptor
- test groups 11 and 12 treated with an inhibitor of insulin-like growth factor receptor (IGF1R) showed higher gene expression on day 6 than test group 10 on day 9, and test group 11 And when test group 12 reached the 9th day, it showed a 10-fold higher expression.
- IGF1R insulin-like growth factor receptor
- IGF1R insulin-like growth factor receptor
- neuroectoderm cells differentiated as a result of the neuroectoderm cell differentiation step (S100) and neuroectodermal cells differentiated by conventional differentiation methods The morphology of cell differentiation by differentiation time point of was observed and compared, and the results are as shown in FIG. 4.
- Neuroectoderm cells that have undergone differentiation by the glutamate neuronal differentiation method from human pluripotent stem cells using the inhibitor of the insulin-like growth factor receptor (GSK1838705A) of the present invention are primitive as shown in FIG. While it has a rosette structure (arrow), when an inhibitor of insulin-like growth factor receptor was not applied (LDN+SB), the structure of the primitive rosette was found to be unclear.
- the neuroectoderm cells in which differentiation was induced by the differentiation method of glutamate neurons from human pluripotent stem cells using the inhibitor of the insulin-like growth factor receptor (GSK1838705A) of the present invention were shown in FIG. As shown, it was confirmed that a number of structures of the definitive rosette (arrow head) observed in the late neurodevelopment were found.
- the neuroectoderm cells in which differentiation was induced by the glutamate neuron differentiation method from human pluripotent stem cells using the inhibitor of the insulin-like growth factor receptor (GSK1838705A) of the present invention were shown in FIG. 4 at the 20th day. As described above, most of the cells are finally differentiated, and most of the cells show typical neurons (neurite structure extending from the center of the cell (nucleus)), whereas insulin-like growth factor receptor inhibitors are not applied (LDN+SB). ), it was confirmed that a number of cells of different shapes were mixed.
- the nerve cells finally obtained when differentiation induction proceeds by the differentiation method of glutamate neurons from human pluripotent stem cells using the inhibitor of the insulin-like growth factor receptor (GSK1838705A) of the present invention. It can be seen that has a high purity (uniform neuronal morphology without mixing of other cells).
- glutamate In order to confirm whether the cytological characteristics of the glutamate neurons differentiated by the method of differentiating glutamate neurons from human pluripotent stem cells using the inhibitor of the insulin-like growth factor receptor of the present invention are intact, glutamate It was confirmed by fluorescence immunostaining that the neurons express well known TUBB3, SYP, and vGLUT1, and the results are as shown in FIG. 5.
- the results of FIG. 5 are the results of confirming whether the differentiated neurons by the glutamate neuron differentiation method from human pluripotent stem cells using the inhibitor of the insulin-like growth factor receptor of the present invention are really glutamate neurons. It was found that the cells showed strong expression intensity for TUBB3, SYP, and vGLUT1 genes, and DAPI drugs were used to stain the cell nucleus.
- the purity of the differentiated neurons was confirmed by the method of differentiating glutamate neurons from human pluripotent stem cells using the inhibitor of the insulin-like growth factor receptor of the present invention, and the results are as shown in FIG. It was high above 95%.
- the expression ratio of TUBB3, a gene of mature neurons was analyzed by FACS analysis of neurons differentiated by the method of differentiating glutamate neurons from human pluripotent stem cells using the inhibitor of the insulin-like growth factor receptor of the present invention. It was confirmed, and as a result, it was verified that the cells have a high purity of more than 96%.
- Microelectrode array (MEA, Axion Biosystems) equipment to measure the electrical activity of neurons differentiated by the method of differentiating glutamate neurons from human pluripotent stem cells using the inhibitor of the insulin-like growth factor receptor of the present invention.
- the spike rate activity was analyzed using, and the results are as shown in FIG. 7.
- the white dots each mean one electrode, which is a situation in which glutamate neurons that have completed the differentiation induction process are in contact with the electrode, and electrical signals generated by the neurons are transmitted through the electrodes. It is converted to a different color according to the intensity. As can be seen from the experimental results, strong electrical signals were shown more than 5 times per second from most of the electrodes, which means that the glutamate neurons induced differentiation using an inhibitor of insulin-like growth factor receptor (GSK1838705A) are functionally mature. do.
- GSK1838705A insulin-like growth factor receptor
- Glutamate neurons differentiated by the method of differentiating glutamate neurons from human pluripotent stem cells using inhibitors of insulin-like growth factor receptors showed 1.5 to 2 times higher gene expression compared to the prior art.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (6)
- 인간 전분화능 줄기세포(hPSC, human Pluripotent Stem Cell)를 N2 및 B27이 포함된 신경외배엽 분화 유도용 배지에서 배양하여 신경외배엽 세포(Neuroectoderm)로 분화 유도시키는 A단계;상기 A단계를 통해 분화 유도된 신경외배엽 세포를 신경전구세포 분화 유도용 배지에서 배양하여 신경전구세포(Neural Progenitor cell)로 분화 유도시키는 B단계; 및상기 B단계를 통해 분화 유도된 신경전구세포를 글루타메이트성 신경세포 분화 유도용 배지에서 배양하여 간 글루타메이트성 신경세포(Glutamatergic neuron)로 분화 유도시키는 C단계;를 포함하며,상기 A단계는 신경외배엽 세포로의 분화 유도를 위해 인간 전분화능 줄기세포(hPSC)가 배양되는 신경외배엽 유도용 배지에 BMP 신호전달체계의 억제제, TGFβ 신호전달체계의 억제제 및 인슐린 유사 성장인자 수용체(IGF1R)의 억제제를 추가 처리하는 단계인 것을 특징으로 하는인슐린 유사 성장인자 수용체의 억제제를 이용한 인간 전분화능 줄기세포로부터의 글루타메이트성 신경세포 분화방법.
- 제1항에 있어서,상기 A단계는 N2 및 B27이 포함된 DMEM/F12 배지에 BMP 신호전달체계의 억제제 150nM 내지 250nM, TGFβ 신호전달체계의 억제제 5μM 내지 15μM 및 인슐린 유사 성장인자 수용체(IGF1R)의 억제제 500nM 내지 1000nM가 추가 처리된 상기 신경외배엽 분화 유도용 배지에서 인간 전분화능 줄기세포를 6일 동안 배양하여 신경외배엽 세포로 분화 유도시키는 단계인 것을 특징으로 하는인슐린 유사 성장인자 수용체의 억제제를 이용한 인간 전분화능 줄기세포로부터의 글루타메이트성 신경세포 분화방법.
- 제2항에 있어서,상기 신경외배엽 분화 유도용 배지는 DMEM/F12 배양액 50ml를 기준으로 N2를 0.4ml 내지 0.6ml의 부피로 포함하고, B27를 0.5ml 내지 1.5ml의 부피로 포함하는 것을 특징으로 하는인슐린 유사 성장인자 수용체의 억제제를 이용한 인간 전분화능 줄기세포로부터의 글루타메이트성 신경세포 분화방법.
- 제1항에 있어서,상기 B단계는 DMEM/F12 배양액 25ml와 Neurobasal 배양액 25ml로 혼합된 배양액을 기준으로 N2를 0.4ml 내지 0.6ml의 부피로 포함하고, B27을 0.5ml 내지 1.5ml의 부피로 포함하는 신경전구세포 분화 유도용 배지에서 상기 A단계를 통해 분화 유도된 신경외배엽 세포를 7일 동안 배양하여 신경전구세포로 분화 유도시키는 단계인 것을 특징으로 하는인슐린 유사 성장인자 수용체의 억제제를 이용한 인간 전분화능 줄기세포로부터의 글루타메이트성 신경세포 분화방법.
- 제1항에 있어서,상기 C단계는,배지에 Poly-L-Ornithine 및 Laminin을 코팅 처리한 뒤, 상기 B단계를 통해 분화 유도된 신경전구세포를 5×10 4 Cells/cm 2의 농도로 접종시키는 C-1단계;상기 C-1단계를 통해 코팅 처리 및 신경전구세포의 접종이 완료된 배지에 Neurobasal 배양액 50ml 및 B27 0.5ml 내지 1.5ml을 포함시키며, BNDF 5ng/ml 내지 15ng/ml, GDNF 5ng/ml 내지 15ng/ml 및 아스코르브산(scorbic acid) 180μM 내지 220μM이 추가 처리되도록 하여 상기 글루타메이트성 신경세포 분화 유도용 배지를 마련하는 C-2단계; 및상기 C-2단계를 통해 마련된 상기 글루타메이트성 신경세포 분화 유도용 배지에서 상기 C-1단계를 통해 접종된 신경전구세포를 7일 이상 배양하여 글루타메이트성 신경세포로 분화 유도시키는 C-3단계;를 포함하는 것을 특징으로 하는인슐린 유사 성장인자 수용체의 억제제를 이용한 인간 전분화능 줄기세포로부터의 글루타메이트성 신경세포 분화방법.
- 제1항 내지 제5항 중 어느 한 항의 인슐린 유사 성장인자 수용체의 억제제를 이용한 인간 전분화능 줄기세포로부터의 글루타메이트성 신경세포 분화방법에 의해 분화된 글루타메이트성 신경세포.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190071402A KR102183230B1 (ko) | 2019-06-17 | 2019-06-17 | 인슐린 유사 성장인자 수용체의 억제제를 이용한 인간 전분화능 줄기세포로부터의 글루타메이트성 신경세포 분화방법 |
KR10-2019-0071402 | 2019-06-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020256162A2 true WO2020256162A2 (ko) | 2020-12-24 |
WO2020256162A3 WO2020256162A3 (ko) | 2021-02-18 |
Family
ID=73645224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/007266 WO2020256162A2 (ko) | 2019-06-17 | 2019-06-17 | 인슐린 유사 성장인자 수용체의 억제제를 이용한 인간 전분화능 줄기세포로부터의 글루타메이트성 신경세포 분화방법 및 이를 통해 마련된 글루타메이트성 신경세포 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102183230B1 (ko) |
WO (1) | WO2020256162A2 (ko) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010144696A1 (en) * | 2009-06-11 | 2010-12-16 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
EP2464723B1 (en) * | 2009-08-12 | 2016-06-22 | Kyoto University | Method for inducing differentiation of pluripotent stem cells into neural precursor cells |
KR101097231B1 (ko) * | 2010-03-23 | 2011-12-21 | 경희대학교 산학협력단 | 신경줄기세포 또는 신경전구세포의 증식 및 분화 촉진용 조성물 |
KR101335485B1 (ko) * | 2011-06-09 | 2013-12-02 | 연세대학교 산학협력단 | 전능성 줄기세포로부터 신경전구세포의 순수분리 및 유지배양 방법 |
CN102604894B (zh) * | 2012-02-29 | 2014-07-30 | 中国科学院广州生物医药与健康研究院 | 用于制备神经干细胞的培养基及其用途 |
WO2016028880A1 (en) * | 2014-08-19 | 2016-02-25 | Cellular Dynamics International, Inc. | Neural networks formed from cells derived from pluripotent stem cells |
TWI589698B (zh) * | 2015-07-22 | 2017-07-01 | 中國醫藥大學 | 間質幹細胞、其純株化擴張之方法、其分離方法及其應用 |
-
2019
- 2019-06-17 WO PCT/KR2019/007266 patent/WO2020256162A2/ko active Application Filing
- 2019-06-17 KR KR1020190071402A patent/KR102183230B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO2020256162A3 (ko) | 2021-02-18 |
KR102183230B1 (ko) | 2020-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7250294B2 (en) | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells | |
Kennea et al. | Neural stem cells | |
CN100535106C (zh) | 使间充质干细胞分化为神经细胞的方法 | |
US7781214B2 (en) | Lineage specific cells and progenitor cells | |
US8492145B2 (en) | Process for producing nerve cells | |
CN111849899B (zh) | 定向诱导hiPSC分化为神经细胞体系的诱导培养基 | |
WO2021086063A1 (ko) | 3차원 뇌 오가노이드를 이용한 뇌신경계질환 치료용 줄기세포 스크리닝 방법 | |
WO2022108117A1 (ko) | 대뇌 오가노이드-모터뉴런 스페로이드 구조체 및 이의 제조방법 | |
WO2016032151A1 (ko) | 콜린성 신경세포의 생산방법 | |
WO2020256162A2 (ko) | 인슐린 유사 성장인자 수용체의 억제제를 이용한 인간 전분화능 줄기세포로부터의 글루타메이트성 신경세포 분화방법 및 이를 통해 마련된 글루타메이트성 신경세포 | |
KR20010021499A (ko) | 계통이 예정된 신경세포 전구체 | |
WO2011159050A2 (ko) | 인간 신경전구세포의 도파민 뉴우런으로의 분화방법 및 분화용 배지 | |
WO2016032152A1 (ko) | 성상세포의 생산방법 | |
CN107475200A (zh) | 一种背根神经节源的神经嵴干细胞的分离、培养与分化方法 | |
WO2020045990A1 (ko) | 합성 메신저 rna를 이용하여 소변세포를 신경줄기세포로 직접 역분화하는 방법 | |
WO2022080974A1 (ko) | 미니뇌 구조체 및 이의 제조방법 | |
McLeod et al. | Transplantation of bioreactor-produced neural stem cells into the rodent brain | |
WO2022239959A1 (ko) | 인간 전분화능 줄기세포 유래 심장 오가노이드 제조 방법 및 이를 통해 제조된 인간 전분화능 줄기세포 유래 심장 오가노이드 | |
WO2023068826A1 (ko) | 자가조립된 rna 구조체를 포함하는 직접교차분화 유도용 조성물 | |
WO2024035134A1 (ko) | 소뇌 오가노이드의 제조방법 | |
WO2016186346A1 (ko) | Oct4가 도입된 인간체세포로부터 직접적 리프로그래밍을 통한 희소돌기아교 전구세포를 유도하는 방법 | |
Yuan-yuan et al. | VCR, a Small Molecule Compound, Induces Reprogramming of Rat Fibroblasts into Neural Progenitor Cells under Hypoxic Condition | |
WO2021235848A1 (ko) | 희소돌기아교세포로 분화가 특화된 신경줄기세포로부터 희소돌기아교세포를 포함하는 오가노이드의 제조방법, 상기 방법으로 제조된 오가노이드 및 이의 용도 | |
WO2024112043A1 (ko) | 인간 타액선 오가노이드와 신경세포종 공배양을 통한 신경성 타액선증 모델링 및 약물 효능 테스트 방법 | |
WO2019177269A1 (ko) | 신경줄기세포를 이용한 혈관형성 유도 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19934112 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19934112 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19934112 Country of ref document: EP Kind code of ref document: A2 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 06/07/2022) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19934112 Country of ref document: EP Kind code of ref document: A2 |